Insulin-like growth factor II (IGF-II) mRNA-binding protein 3 (IMP3) is emerging as a useful indicator of the progression and outcome of several cancers. IMP3 expression is associated with triple-negative breast carcinomas (TNBCs), which are aggressive tumors associated with poor outcome. In this study, we addressed the hypothesis that signaling pathways, which are characteristic of TNBCs, impact the expression of IMP3 and that IMP3 contributes to the function of TNBCs. The data obtained reveal that IMP3 expression is repressed specifically by estrogen receptor b (ERb) and its ligand 3bA-diol but not by ERa. Epidermal growth factor receptor (EGFR) signaling and consequent activation of the mitogen-activated protein kinase pathway induce IMP3 transcription and expression. Interestingly, we discovered that the EGFR promoter contains an imperfect estrogen response element and that ERb represses EGFR transcription. These data support a mechanism in which ERb inhibits IMP3 expression indirectly by repressing the EGFR. This mechanism relates to the biology of TNBC, which is characterized by diminished ERb and increased EGFR expression. We also demonstrate that IMP3 contributes to the migration and invasion of breast carcinoma cells. Given that IMP3 is an mRNA-binding protein, we determined that it binds several key mRNAs that could contribute to migration and invasion, including CD164 (endolyn) and MMP9. Moreover, expression of these mRNAs is repressed by ERb and enhanced by EGFR signaling, consistent with our proposed mechanism for the regulation of IMP3 expression in breast cancer cells. Our findings show that IMP3 is an effector of EGFR-mediated migration and invasion and they provide the first indication of how this important mRNA-binding protein is regulated in cancer.
INTRODUCTION
IMP3 is a member of a family of insulin-like growth factor II (IGF-II) mRNA-binding proteins (IMPs), consisting of IMP1, IMP2 and IMP3. 1 IMPs have important roles in RNA trafficking, stabilization, localization and cell migration, especially during early stages of both human and mouse embryogenesis. 2 IMPs are expressed in developing epithelium, placenta and muscle, but they are undetectable in normal adult tissues. 3 Importantly, however, IMP3 is re-expressed in several malignant tissues, including pancreatic, lung, renal cell, ovarian, endometrial and cervical cancers. 4 --9 This phenomenon has been exploited for the prognostic assessment of specific cancers. In particular, IMP3 is an accurate predictor of renal-cell carcinoma metastasis and prognosis, 4 and similar trends are emerging for other cancers. 10 --12 We are interested in breast cancer in this context, especially in light of the finding that IMP3 is expressed preferentially in triplenegative breast cancers. 10 Triple-negative breast cancer (TNBC) is a molecular subtype of breast cancer characterized by the absence of estrogen receptor-a (ERa), progesterone receptor and human epidermal growth factor receptor-2 amplification. Clinically, TNBCs are usually of high histological grade, poorly differentiated and more aggressive compared with other subtypes of breast cancer. 13 In fact, treatment of TNBC patients remains a challenge because of the lack of targeted therapeutic options and the high metastatic potential of TNBC cells. These observations indicate that IMP3 could prove useful for the clinical management of TNBC but much remains to be learned about its regulation and function in these tumors.
In this study, we addressed the hypothesis that signaling pathways, which are characteristic of TNBCs, impact the expression of IMP3 and that IMP3 contributes to the function of TNBCs. A salient feature of TNBC is the absence of or diminished ER signaling. More specifically, TNBCs are ERa negative and they express low levels of ERb. 14 A reasonable possibility based on these observations is that ER signaling represses IMP3. Interestingly, our data reveal that ERb and its ligand 3bA-diol (5a-Androstane-3b, 17b-diol) repress IMP3 expression but that ERa does not contribute to this repression. Further analysis demonstrated that epidermal growth factor receptor (EGFR) signaling induces IMP3 expression and that ERb represses EGFR transcription, revealing a mechanism in which ERb inhibits IMP3 expression indirectly by repressing the EGFR. This finding is relevant to the biology of TNBC because these tumors are characterized by overexpression of the EGFR and concomitant EGFR signaling. 15 Our observation that IMP3 contributes to the migration and invasion of TNBC cells provides a functional role for this IMP in breast cancer, and it suggests that IMP3 can be an effector of EGFR-mediated migration and invasion.
RESULTS

ERb suppresses IMP3 expression
To assess the possible role of ERs in regulating IMP3 expression, we used MDA-MB-231 and MDA-MB-468 cells, which are TNBC cell lines that express IMP3 but lack ERa and express low levels of ERb. Exogenous expression of ERa in MDA-MB-231 cells did not alter IMP3 expression ( Figure 1a ). Also, inhibition of endogenous ERa activity by ICI-182780 (a selective ERa antagonist) was unable to induce IMP3 expression in MCF7 cells, which express ERa and ERb but not IMP3 (Figure 1a ). Based on these results, we focused our attention on ERb. PHTPP (4 --2 --phenyl-5, 7 --bis (trifluoromethyl) pyrazolo (1,5 --a) pyrimidin-3 --yl phenol) is a specific ERb antagonist and it caused a significant increase in IMP3 expression in both MDA-MB-231 and MDA-MB-468 cells (Figure 1b ). This finding was substantiated using 3bA-diol, an androgen metabolite that is a specific ligand of ERb. 16 3bA-diol decreased IMP3 expression in MDA-MB-231 cells indicating that ligand-dependent activation of ERb represses IMP3 (Figure 1c ). Also, depletion of ERb, using small hairpin RNAs, increased IMP3 expression in both MDA-MB-231 and MDA-MB-468 cells significantly ( Figure 1d ). Interestingly, PHTPP did not induce IMP3 expression in MCF7 cells (Figure 1e ), indicating that the ERb-mediated repression of IMP3 may be restricted to TNBC cells.
We observed that estrogen (E 2 ) increased IMP3 expression in MDA-MB-231 cells (Figure 1f ). Although this result seems unexpected, we also found that estrogen increased EGFR phosphorylation in these cells ( Figure 1f ) and that the ability of estrogen to increase EGFR phosphorylation was not affected by either inhibition (PHTPP) or stimulation (3bA-diol) of ERb function ( Figure 1f ). These findings are consistent with the report that estrogen exerts its non-genomic action through EGFR signaling. 17 EGFR signaling positively regulate IMP3 expression Given that high EGFR expression is associated with TNBC, 15 we assessed the possibility that EGFR signaling regulates IMP3 expression. Treatment of both MDA-MB-231 and MDA-MB-468 cells with an EGFR function-blocking antibody (Ab) reduced IMP3 expression significantly compared with IgG-treated cells (Figure 2a ). This Ab also diminished EGFR phosphorylation and MAP (mitogen-activated protein) kinase activation, which is a bona fide downstream effector of the EGFR signaling pathway 18 (Figure 2a ). To substantiate the involvement of EGFR signaling pathway in regulating IMP3 expression, we inhibited MEK1/2 (upstream component of MAPK) using two different inhibitors (PD98059 and U0126). As shown in Figure 2b , IMP3 mRNA and protein expression is reduced significantly upon treatment with these inhibitors. Similar results were obtained using MDA-MB-468 cells (Figure 2c ). We also assayed the activity of the IMP3 promoter in the presence of the MEK1/2 inhibitors using a reporter construct containing the human IMP3 proximal promoter. As shown in Figure 2d , inhibition of MEK1/2 using either U0126 or PD98059 decreased luciferase activity considerably. Collectively, our data indicate that an EGFR/MEK/MAPK pathway regulates IMP3 expression.
ERb suppresses EGFR expression
The contrasting data we obtained with ERb and EGFR regulation of IMP3 expression raised the possibility that these receptors function in a common pathway. This possibility was supported by our observation that depletion of ERb expression in both MDA-MB-231 and MDA-MB-468 cells increased EGFR mRNA and protein expression significantly compared with control cells expressing GFP (green fluorescent protein) small hairpin RNA (Figures 3a and b) . Similarly, overexpression of ERb reduced EGFR protein and mRNA ( Figure 3c ). To substantiate our hypothesis, we inhibited ERb function using the selective antagonist PHTPP and observed increased EGFR protein expression ( Figure 3d ). In contrast, PHTPP did not induce EGFR expression in MCF7 cells ( Figure 3d ). Interestingly, restoration of ERa expression in MDA-MB-231 cells did not affect EGFR expression ( Figure 3e ), consistent with our finding that ERa does not contribute to the regulation of IMP3. The EGFR promoter contains an imperfect estrogen response element (ERE) at 1.949 kb (AATCAACGTGAAT) suggestive of the possibility that ERb may repress EGFR transcription. This imperfect ERE was identified on the basis of its homology with the imperfect ERE present in the human vascular endothelial growth factor promoter, which is 5 0 -AATCAGACTGACT-3 0 . 19 The putative ERE present in the EGFR promoter differs from that in the vascular endothelial growth factor promoter by a single nucleotide 'A' as shown in italics, whereas the imperfect ERE present in the vascular endothelial growth factor promoter differs from the perfect ERE (GGTCAnnnTGACC) 20 by three nucleotides (underlined). This observation suggested that the core ERE sequence TCAnnnTGA is critical for the sequence to be functional. To assess the contribution of this sequence to EGFR regulation, we generated reporter constructs containing the 2.2-kb wild-type EGFR promoter or this construct containing a mutation in the core sequence (TCAACGTGA to CATACGTGA). The data obtained with these constructs revealed that mutation of the imperfect ERE increased luciferase activity by B2-fold suggesting that this sequence has a repressive role in EGFR transcription (Figure 3f ).
IMP3 increases migration and invasion of breast cancer cells
Given that triple-negative breast cancers are more aggressive, possess high metastatic potential and overexpress IMP3, 10, 13 it is reasonable to hypothesize that IMP3 contributes to their aggressive behavior. To address this hypothesis, we depleted IMP3 expression in MDA-MB-231 cells using siRNA and assessed their ability to migrate and invade using transwell assays. As shown in Figure 4a IMP3 is supported by the observation that U0126, a MEK inhibitor, reduced migration and invasion significantly (Figure 4f ). The fact that IMP3 is an mRNA-binding protein suggests that it contributes to migration and invasion by regulating specific mRNAs. The obvious target for IMP3 is IGF-II but depletion of IMP3 in MDA-MB-231 cells or expression in MCF-7 cells had no effect on IGF-II mRNA expression (Figures 5a and b) . Several putative mRNA targets of IMP3 were recently identified based upon PAR-CLIP (photoactivatable-ribonucleoside-enhanced-crosslinking and immunoprecipitation) 21 that could contribute to cell motility and invasion. These targets include CD164 (endolyn), RhoA, CCNG1 and CCND2, which are known to have a role in carcinogenesis. 22 --25 We assayed these candidate mRNAs by qPCR (quantitative PCR) in IMP3-depleted MDA-MB-231 cells and in MCF7 cells engineered to express IMP3. Although no significant change in RhoA, CCNG1 and CCND2 mRNA expression was observed (data not shown), CD164 mRNA expression was significantly decreased in IMP3-depleted MDA-MB-231 cells and it was increased in IMP3-expressing MCF7 cells (Figures 5c and d) . We also assayed the hyaluronan receptor CD44 expression because it is known to contribute to tumor progression and there is evidence that it can be regulated by IMP3 in HeLa cells. 26 Our data, however, did not support IMP3-mediated regulation of CD44 mRNA expression in breast carcinoma cells ( Figure 5e ). CD44 functions as a docking site for the matrix metalloproteinase MMP9, which contributes to invasion. 27 Although MMP9 had not been identified as an IMP3 target, however, we observed that MMP9 mRNA expression is regulated by IMP3 (Figures 5c and d) . We performed Ribo-immunoprecipitation-qPCR analysis to establish that IMP3 indeed binds with IGF-II, MMP9 and CD164 mRNA (Figure 5f ).
Based on our findings, IMP3 mRNA targets that we identified should be regulated by ERb and EGFR. Indeed, depletion of ERb increased the expression of MMP9 and CD164 mRNAs significantly in MDA-MB-231 cells (Figure 6a ). In contrast, Ab-mediated inhibition of the EGFR decreased the expression of these mRNAs (Figure 6b ). We also observed a significant reduction in the expression of these mRNAs in cells treated with MEK1/2 inhibitor U0126 (Figure 6c ).
DISCUSSION
The data obtained in this study provide insight into the mechanisms that regulate the expression of IMP3 in breast carcinoma cells and that are associated with the function of this mRNA-binding protein in migration and invasion. Our data revealed that IMP3 expression is repressed by ERb but not ERa, and that it is stimulated by EGFR signaling. More specifically, we demonstrate that ERb represses transcription of the EGFR and that EGFR signaling regulates IMP3 expression directly (Figure 7 ). An important and novel implication of this study is that IMP3 is an effector of EGFR-driven migration and invasion. Our findings have important implications for the biology and therapy of TNBC, which is characterized by elevated expression of EGFR and IMP3, 10,28 and reduced expression of ERb. 14 Our results highlight a role for ERb in regulating the functions of breast carcinoma cells that is distinct from ERa. It is surprising that a role for ERa in regulating IMP3 expression was not revealed by our data because loss of ERa is a defining characteristic of TNBC. 29 Establishing a distinct function for ERb is significant because much less is known about ERb than ERa in breast cancer biology. In addition to its ability to repress IMP3, ERb has been shown to inhibit breast cancer cell proliferation and invasion by suppressing cell cycle genes, including c-Myc, cyclin D1 and cyclin A. 30 The report that ERb expression correlates inversely with tumor grade 14 supports our conclusion that ERb represses IMP3 because TNBC is usually high grade. Our data also indicate that there is ligand specificity in the regulation of IMP3 expression. Specifically, we demonstrated that 3bA-diol functions as an ERb-specific ligand that represses IMP3 expression. Estrogen, in contrast, actually increased IMP3 expression in TNBC cells. Given that these cells are ERa-negative, we conclude that this effect of estrogen is nongenomic and it may be explained by its effect on EGFR signaling. 17 This conclusion is supported by our observation that estrogen increased EGFR phosphorylation in ERa-negative cells independently of ERb function. An unexpected and novel finding in this study is that ERb represses EGFR expression and signaling, possibly through its ability to repress EGFR transcription. Our identification of an imperfect ERE sequence in the EGFR promoter and demonstration that this sequence represses EGFR transcription supports this hypothesis. Moreover, there is precedence in the literature that ERb can repress transcription by recruiting co-repressors such as NCoR. 31 There is also indirect evidence that expression of ERb in malignant pleural mesothelioma (MME) cells impedes EGFR signaling. 32 An important issue that arises from these observations is the extent to which diminished ERb expression in TNBC contributes to the elevated expression of EGFR that is characteristic of this breast cancer subtype. There is evidence that EGFR gene amplification is more common in TNBCs than non-TNBCs, 33 but the possibility that a reduction in ERb expression functions in concert with gene amplification should be considered.
The relationship between EGFR and IMP3 that we uncovered has important implications for the biology and therapy of breast cancer. EGFR signaling has profound effects on the proliferation, survival and invasion of tumor cells. 15 Enhanced expression of EGFR in primary breast tumors predicts poor prognosis and renders them more aggressive. 34 --37 In the context of our findings, EGFR-driven migration and invasion contribute to tumor progression and metastasis, and the mechanisms involved have been the focus of numerous studies. 38 --40 We conclude from our findings that IMP3 can be an effector of EGFR-driven migration and invasion, and suggest that this contribution of IMP3 needs to be integrated with other mechanisms of EGFR-mediated migration and invasion. From a clinical perspective, the EGFR is considered to be a viable target for therapy of TNBC. Although small-molecule EGFR inhibitors, including gefitinib (Iressa) and the monoclonal antibody cetuximab, are in clinical trials for this aggressive subtype of breast cancer, 41 none of these drugs has shown efficacy till date. We postulate based on our data that smallmolecule inhibitors of IMP3 would augment anti-EGFR therapy for the treatment of TNBC.
The overarching issue raised by our data is how IMP3 contributes to the aggressive behavior of breast cancers. In fact, this issue is important for several cancers in which IMP3 expression has been correlated with progression and poor outcome. 4,7,10 A role for IMP3 in invasion was foreshadowed by the finding that IMPs (specifically IMP1 and IMP3) induce invadopodia formation by regulating the expression of CD44 in HeLa cells. 26 Although our data did not reveal that CD44 expression is regulated by IMP3 in breast cancer, the induction of invadopodia formation by IMPs is consistent with our data. Recent studies have implicated IMP3 in the migration of HeLa cells 6 and in the aggressive behavior of glioblastoma cells including invasion. 42 In addition to a role in migration and invasion, IMP3 has been implicated in proliferation, anchoragedependent cell growth and survival. 42, 43 However, depletion of IMP3 expression in breast carcinoma cells did not affect cell cycle and anchorage-dependent growth (data not shown).
Given that IMP3 is an mRNA-binding protein, the most feasible hypothesis to account for its role in migration and invasion is that it affects the expression or localization of specific mRNAs that are critical for invasion and progression. Our finding that IMP3 binds and stabilizes CD164 and MMP9 mRNAs provides potential insight into this hypothesis. CD164, a cell surface receptor for sialomucin, has been implicated in prostate cancer metastasis 22 and MMP9, a type-IV collagenase, contributes to carcinogenesis by several mechanisms including degradation of the basement membrane 44 and promoting the release of growth factors from the extracellular matrix. 45 Moreover, MMP9 expression is correlated with poor prognosis in node-negative breast cancer. 46 Another relevant observation in our study is that IMP3 binds IGF-II and CD44 mRNAs but it does not alter their expression. This finding is distinct from other reports that have shown that IMP3 can activate the translation of IGF-II in leukemia cells 47 and glioblastoma cells, 42 and regulate the expression of CD44 in Hela cells. 26 The possibility Figure 7 . Proposed model for how ERb regulates IMP3 in triplenegative breast cancer cells. The interaction of ERb with its ligand 3bA-diol suppresses EGFR expression. EGFR signaling induces IMP3 expression. IMP3 facilitates the migration and invasion of triplenegative breast carcinoma cells by a mechanism that may involve its ability to bind specific mRNAs, such as CD164 and MMP9.
that IMP3 regulates the localization or other aspects of these mRNAs merits investigation because both IGF-II and CD44 are important in the biology of breast cancer. 48, 49 In summary, our data provide the first insight into mechanisms that regulate the expression of an mRNA-binding protein that is associated with TNBC and that is prognostic for progression and outcome in other cancers. These regulatory mechanisms are intimately linked to the biology of TNBC and they also reveal a novel mechanism of EGFR-driven migration and invasion. Our data also suggest that targeted-IMP3 therapy could augment EGFR inhibition in the treatment of TNBC.
MATERIALS AND METHODS
Cells, reagents and treatments
The breast cancer cell lines MDA-MB-231, MDA-MB-468 (mentioned as MDA-231 and MDA-468 in the figures) and MCF7 were obtained from American Type Culture Collection and maintained in Dulbecco's modified Eagle medium (low glucose) containing 10% fetal bovine serum, 1% streptomycin and penicillin at 37 1C in an incubator supplied with 5% CO 2 . IMP3-specific siRNA was purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). A non-targeting pool was used as negative control. Dharmafect-4 was used for siRNA delivery and was purchased from Thermo Scientific (Rockford, IL, USA). Lipofectamine-2000 was used for regular DNA transfection and purchased from Invitrogen (Grand Island, NY, USA). The control plasmid vector pcDNA3 was purchased from Invitrogen and pcDNA4/His/Max was a gift from Dr Michael Green, UMass Medical School. The lentiviruses (PLKO.1) containing ER-b small hairpin RNAs or shGFP (Open Biosystems, Lafayette, CO, USA, clone ID: TRCN0000003326, TRCN0000003327 and RHS4459) were generated in HEK293T cells and infected in MDA-MB-231 cells following standard protocols described elsewhere. 50 The MEK1/2 inhibitors U0126 and PD98059 were purchased from LC Laboratories (Woburn, MA, USA). ICI was purchased from Sigma-Aldrich (St Louis, MO, USA). The IMP3 antibody was obtained from DAKO, (Hamburg, Germany). ERa, EGFR and pEGFR (Tyr-1263) Abs were purchased from Santa Cruz Biotechnology Inc. pMAPK (p42/44) and pAkt (ser473) Abs were obtained from Cell Signaling Technology (Danvers, MA, USA). The ERb antibody was purchased from Gen Tex Inc (Irvine, CA, USA). The IGF-II and CD44 antibodies were purchased from Abcam (Cambridge, MA, USA). Estrogen (E 2 ), PHTPP and 3bA-diol were purchased from Tocris Biosciences (Minneapolis, MN, USA) and dissolved in dimethylsulphoxideDMSO. For 3bA-diol treatment, MDA-MB-231 cells were cultured in DMEM (low glucose) supplemented with 5% charcoal-stripped fetal bovine serum. For treatment with all other reagents, cells were cultured in normal medium (mentioned above) and serum-starved for 24 h prior to treatment.
Immunoblotting
Whole cell extracts were prepared using radioimmunoprecipitation assay buffer containing EDTA and ethylene glycol tetraacetic acid (Boston Bioproducts, Ashland, MA, USA). A protease-and phosphatase-inhibitor cocktail was added separately (Roche Applied Science, Indianapolis, IN, USA). Extracts (40 --50 mg protein) were blotted with the appropriate primary Abs and then incubated with mouse or rabbit IgG horseradish peroxidase-conjugated secondary antibody. ECL kit (Pierce Biotechnology, Rockford, IL, USA) was used to develop the blots.
RNA isolation and real-time PCR analysis
Total RNA was isolated from cultured cells using Trizol reagent (Invitrogen) following the manufacturer's protocol. Complementary DNA was synthesized using superscript-II reverse transcriptase (Invitrogen). mRNAs were quantified by real-time PCR analysis (ABI Prism, Applied Biosystems, Carlsbad, CA, USA) using Power Syber Green PCR master mix (Applied Biosystems). Quantification was performed using DDCt method and GAPDH was used as reference gene. The following primer pairs were used for real-time PCR analysis: IMP3-forward: 5 0 -CCGCAGTTTGAGCAATCAGAA-3 0 IMP3-reverse: 5 0 -CGAGAAAGCTGCTTGATGTGC-3 0 EGFR-forward: 5 0 -GCCCCCACTGCGTCAAGACC-3 0 EGFR-reverse: 5 0 -ACCTGGCCCAGTGCATCCGT-3 0 ERb-forward: 5 0 -AAGGTTAGTGGGAACCGTTG-3 0 ERb-reverse: 5 0 -ACATCCTTCACACGACCAGA-3 0 MMP9-forward: 5 0 -TTTGACAGCGACAAGAAGTGG-3 0 MMP9-reverse: 5 0 -AGGGCGAGGACCATAGAGG-3 0 CD164-forward: 5 0 -GAGTGCTGTAGGATTAATTGGAAAAT-3 0 CD164-reverse: 5 0 -GGGAGGAATGGAATTCTGC-3 0 IGFII-forward: 5 0 -CCGAAACAGGCTACTCTCCT-3 0 IGFII-reverse: 5 0 -AGGGTGTTTAAAGCCAATCG-3 0 CD44-forward: 5 0 -GCCCTTCCATAGCCTAATCC-3 0 CD44-reverse: 5 0 -CTTTGGTGTCTCCCAGAAGC-3 0 .
Migration and invasion assays
Assays were performed using transwell chambers (8-mm polycarbonate membrane, Costar, Corning Inc, Horseheads, NY, USA) that had been coated with either collagen I or Matrigel (BD Biosciences, Billerica, MD, USA) for migration and invasion, respectively, as described previously. 51 Assays were quantified by counting the number of stained nuclei in five independent fields in each transwell.
Ribo-immunoprecipitation-qPCR
Identification of endogenous mRNA targets of IMP3 was performed by riboimmunoprecipitation assay, as described previously with minor modifications. 47 Briefly, MDA-MB-231 cells (B2 Â 10 7 ) were harvested and extracted for 15 min on ice in 250 ml of ice-cold lysis buffer (100 mm KCl, 5 mm MgCl 2 , 10 mm HEPES (pH 7.0), 0.5% Nonidet P-40, 10 mm dithiothreitol) supplemented with RNase and protease inhibitors (1 ml of lysis buffer contains 5.25 ml of 40 units/ml RNase OUT (Invitrogen), 2 ml of 0.2% vanadyl ribonucleoside complexes (New England Biolabs, Beverly, MA, USA), 50 ml of complete protease inhibitor mixture (Roche Applied Science). Extracts were cleared by centrifugation for 15 min at 13 000 r.p.m. and supernatant was transferred to a fresh 1.5-ml tube. To pre-clear the cytoplasmic extracts, 25 mg of non-immune rabbit IgG (Sigma-Aldrich) was added to the supernatant and kept on ice for 45 min, then incubated with 50 ml of a 50% (v/v) suspension of protein G-Sepharose beads (Biovision, San Francisco, CA, USA) for 3 h at 4 1C with rotation. This was centrifuged at 13 000 r.p.m. and the supernatant was recovered (pre-cleared lysate). For immunoprecipitation, the pre-cleared extract was incubated with 100 ml of a 50% suspension of protein G-Sepharose beads (Sigma-Aldrich) precoated with the same amount of either non-immune rabbit IgG (Sigma-Aldrich) or anti-human IMP3 antibody (25 mg) in 800 ml of NT-2 buffer (150 mm NaCl, 1 mm MgCl 2 , 50 mm Tris--HCl (pH 7.4), 0.05% Nonidet P-40) containing RNase inhibitor and protease inhibitors for overnight at 4 1C with rotation. Beads were washed 10 times using ice-cold NT-2 buffer, digested with 20 units of RNase-free DNase I (Promega, Madison, WI, USA) in 100 ml of NT-2 buffer for 20 min at 30 1C, washed with NT-2 buffer, and further digested with 0.5 mg/ml protease K (Ambion, Grand Island, NY, USA) in 100 ml of NT-2 buffer containing 0.1% sodium dodecyl sulphate at 55 1C for 30 min. RNA was extracted with Trizol (Invitrogen). Glycogen (Roche Applied Science) was added to facilitate precipitation of RNA. Realtime PCR was performed with equal amount of RNA to detect IGF-II, MMP9 and CD164 mRNAs using previously described primers.
IMP3 and EGFR promoter analysis
The human IMP3 promoter (2.872 kb) was PCR amplified from human genomic DNA. The PCR-amplified fragments were confirmed by restriction mapping and cloned at the NheI-Hind III sites into the pGL3 basic vector (Promega). Similarly, the EGFR promoter (2.2 kb) was cloned and ERE (AATCAACGTGAAT) was mutated to (AACATACGTGAAT) using site-directed mutagenesis (QuikChange XL site-directed mutagenesis kit, Agilent Technologies, Santa Clara, CA, USA). Primer pairs used: IMP3 promoter: Forward: 5 0 -TATGATGCTAGCACTTGAAGTGCTAGTGCA AGACAACT Reverse: 5 0 -CAGTAGAAGCTTTCCACCAGTCTTCCTAAGTCTTAGGA
